RxDoctor Payments Data

Victor Gura, MD

Nephrology · Beverly Hills, CANPI 1932296357

Payments from drug & device makers

$2,141in general payments, 2019–2025

Across 27 payments — averaging $79.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Outset Medical Inc$426
  • Boehringer Ingelheim$248
  • AstraZeneca$236
  • Novo Nordisk$235
  • Bridgebio Pharma, Inc.$167
  • Amgen$150
  • plus $679 from 8 others

What the payments were for

  • Food & beverage$2,141100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,141 in reported general payments places this provider in the 55th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$539,160
Medicare patients
274
Services billed
5,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin151$113,938
OzempicSemaglutide97$99,546
VelphoroSucroferric Oxyhydroxide38$87,708
ProcritEpoetin Alfa14$54,323
Repatha SureclickEvolocumab49$34,058
EliquisApixaban40$32,659
JanuviaSitagliptin Phosphate31$30,846
Evenity (2 Syringes)Romosozumab-Aqqg11$27,338
AuryxiaFerric Citrate19$27,337
MounjaroTirzepatide26$25,967
LokelmaSodium Zirconium Cyclosilicate19$19,512
VascepaIcosapent Ethyl37$15,674
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate25$14,785
EdarbiAzilsartan Medoxomil39$13,974
EntrestoSacubitril/Valsartan17$13,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$248$113,938151 claims
Novo NordiskOzempic$235$99,54697 claims
PfizerEliquis$20$32,65940 claims
AmgenEvenity (2 Syringes)$150$27,33811 claims
Akebia Therapeutics IncAuryxia$19$27,33719 claims
Lilly USA, LLCMounjaro$16$25,96726 claims
AstraZenecaLokelma$236$19,51219 claims
NovartisEntresto$137$13,85417 claims
BayerKerendia$133$9,53113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,341 nephrology providers in California.

Other nephrology in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →